e1%; ELSEVIER Author Index for Volume 16 Amoroso WP, 104S Fairweather WR, 456 Kelder SH, 96 Anderson JJ, 342 Fayers P, 173 Knatterud GL, 139 Applegate WB, 41 Feig] P, 150 Koch HJ, 182 Arango IG, 422 Feldman HA, 96 Kramer BS, 150 Armitage P, 259 Felson DT, 342 Kuntz TE, 104S Fleming TR, 408 Kupfer D, 17 Bagniewska A, 66S Ford LG, 150 Bailey LR, 30S Foulkes M, 408 Lakatos E, 96 Baldwin W, 300 Foulkes MA, 277, 310 Leahy KA, 51 Barnes TY, 164 Frank E, 17 Lewis SM, 89 Barton F, 432 Fraser WD, 299 Lind BK, 4S Bayer DP, 187 Freedman LS, 277, 310 Liu P-Y, 119 Benson V, 3 Friedman L, 277, 310 LoPresti F, 30S Blumenstein B, 150, 453 Blumenstein BA, 4S Gail MH, 230 Mantel N, 197, 214 Boissel J-P, 286, 319 Gassman JJ, 1045S Martin JP, 104S Borok GM, 3 Geller NL, 277, 310 Mayer KH, 408 Brawley OW, 150, 293 George VA, 422 McBride R, 1S, 137S Bring J, 131 Gerace TA, 422 McCormick M, 41 Buist AS, 184, 296 Germanson TP, 164 McFadden ET, 30S Gibson D, 173, 455 McKenna C, 89 CATCH Study Group, 96 Girard P, 319 McKinlay SM, 96 Charache S, 432 Goldman S, 331 McMahon RP, 432 Chauvin F, 319 Gordon DJ, 41, 277, 310 Meinert C, 139 Chernoff MC, 342 Gore SM, 289 Meinert CL, 304, 363 Childress JF, 408 Green SB, 189 Menzin J, 3 Choi SC, 164 Greenhouse J, 17 Mitchell HE, 4S Clarke E, 30S Greenhouse SW, 191, 214 Moher D, 62 Clarke WR, 301 Greenlick MR, 296 Moore R, 432 Cohen MC, 89 Griffiths RI, 377 Moritz T, 331 Moses LE, 216 Coltman CA, Jr, 150 Gueyffier F, 286 Mossman J, 173 Comstock GW, 133 Copeland J, 331 Harrington M, 270 Mowery R, 277, 310 Muller JE, 89 Crowley J, 150 Harvey AJ, 455 Multicenter Study of Curtis RC, 41 Haugh M, 286, 319 Hydroxyurea, 432 Hawkins BS, 66S, 458 Dahlberg S, 119 Henderson WG, 331 Murray DM, 96 Davis CE, 41 Hertert S, 184 DeMets DL, 408 Heyse JF, 3 Nader PR, 96 Dover G, 432 Horbar JD, 51 Newhouse MM, 66S Doyle SR, 451 Hosking JD, 66S Ng T-H, 356 Nichol G, 62 Dudl RJ, 3 Durieu I, 319 Jadad AR, 62 Nony P, 319 James KE, 4S Eckert S, 432 Jones MF, 301 OFallon J, 408 Ellenberg SS, 408 Omoigui NA, 143 Epstein A, 3 Kadane JB, 313 Osborne ML, 184 Epstein RS, 3 Kamlet MS, 17 Oster G, 3 Controlled Clinical Trials 16:460-461 (1995) © Elsevier Science Inc. 1995 0197-2456/95/$9.50 655 Avenue of the Americas, New York, NY 10010 SSDI 0197-2456(95)00191-3 Author Index for Volume 16 461 Overall JE, 451 Schneiderman MA, 193, 214 Vermont-Oxford Trials Owen WW, 104S Sethi G, 331 Network, 51 Shih JH, 395 Vollmer WM, 184 Parmar MKB, 455 Simon R, 277, 310 Paul N, 17 Singer SW, 1S, 137S, 363 Waclawiw M, 432 Penman M, 62 Stevens MT, 447 Wade M, 17 Piantadosi S, 202, 214, 307 Straus S, 408 Walsh S, 62 Pollard RB, 408 Walters L, 408 Powe NR, 377 . Wang M, 342 Terrin ML, 432 Webber LS, 96 Prentice RL, 249 The SvO, Collaborative Whitley RJ, 408 Quinn V, 3 Group, 74 Whitley-Williams P, 408 gle Wilkins PC, 30S Rahal JJ, 408 Topol EJ, 143 Wittes JT, 1 Rochon J, 449 Torner JC, 301 Wolf M, 150 Tugwell P, 62 Woolson RF, 301 Sande M, 408 Sato T, 359 Uryniak TJ, 447 © Zucker DM, 96 | mm W1k ; ELSEVIER Subject Index for Volume 16 ABSTRACTS BYAR, DAVID P., M.D. Abstracts from the Sixteenth Annual Byar, David P., M.D., 187 Meeting of the Society for Clinical Trials, 3S CANCER CLINICAL TRIALS UKCCCR Register of U.K. Cancer Trials, ADHERENCE 172 An Empirical Evaluation of the Placebo CANCER EPIDEMIOLOGY Run-in, 41 David Byar’s Approach to the Analysis of Survival Data with Covariates, 259 AIDS The Data and Safety Monitoring Board and CHECKLISTS Acquired Immune Deficiency Assessing the Quality of Randomized Syndrome (AIDS) Clinical Trials, Controlled Trials: An Annotated 408 Bibliography of Scales and In Memoriam: David Byar as an AIDS Checklists, 62 Activist, 170 CHEMOPREVENTION ANGIOPLASTY Design of the Prostate Cancer Prevention Observational versus Randomized Medical Trial (TCPT), 150 Device Testing Before and After Approval-— The Atherectomy- CLINICAL ECONOMICS versus-Angioplasty Controversy, The Clinical-Economic Trial: Promise, 143 Problems, and Challenges, 377 ASSESSMENT CLINICAL TRIALS Assessing the Quality of Randomized A Simple Measure in Defining Optimal Controlled Trials: An Annotated Strata in Clinical Trials, 164 Bibliography of Scales and Checklists, 62 CLINICAL TRIAL An Assessment of Data Quality in the Vermont-Oxford Trials Network ATHERECTOMY Database, 51 Observational versus Randomized Medical Device Testing Before and After CLINICAL TRIALS approval — The Atherectomy- An Empirical Evaluation of the Placebo versus-Angioplasty Controversy, Run-in, 41 143 The Clinical-Economic Trial: Promise, Problems, and Challenges, 377 BIASED ASCERTAINMENT Commentary regarding “Inclusion of Design of the Prostate Cancer Prevention Women and Minorities in Clinical Trial (TCPT), 150 Trials and the NIH Revitalization Act of 1993—The Perspective of the BOOK REVIEWS NIH Clinical Trialists,” 307 Clinical Data Management, ed. Rondel RK, Comments on NIH Clinical Trials Valid Varley SA, and Webb, CF, 458 Analysis Requirements, 304 Drug Safety Assessment in Clinical Trials, The Data and Safety Monitoring Board and by Sogliero-Gilbert G, 456 Acquired Immune Deficiency Controlled Clinical Trials 16:462-468 (1995) © Elsevier Science Inc. 1995 0197-2456/95/$9.50 655 Avenue of the Americas, New York, NY 10010 SSDI 0197-2456(95)00192-1 Subject Index for Volume 16 Syndrome (AIDS) Clinical Trials, COORDINATING CENTERS 408 Functions and Organization of David Byar’s Approach to the Analysis of Coordinating Centers for Survival Data with Covariates, 259 Multicenter Studies, 4S Discussion of “Inclusion of Women and Minorities in Clinical Trials and the COST-BENEFIT STUDIES NIH Revitalization Act of 1993 — The The Clinical-Economic Trial: Promise, Perspective of NIH Clinical Problems, and Challenges, 377 Trialists,” 301 Format-Independent Data Collection COST EFFECTIVENESS Forms, 363 A Randomized Trial to Assess Effectiveness Inpact of the NIH Inclusion Guidelines, 300 and Cost in Clinical Practice: Inclusion of Women and Minorities in Rationale and Design of the Clinical Trials, 290 Cholesterol Reduction Intervention Study (CRIS), 3 Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1933—The COST-EFFECTIVENESS STUDIES The Clinical-Economic Trial: Promise, Perspective of NIH Clinical Problems, and Challenges, 377 Trialists, 277 Problems and Suggested Solutions in COST-UTILITY ANALYSIS Creating an Archive of Clinical Cost Utility Analysis of Maintenance Trials Data to Permit Later Treatment for Recurrent Meta-Analysis: An Example of Depression, 17 Methotrexate Trials in Rheumatoid Arthritis, 342 CRITICALLY ILL PATIENT Response Rates to Six Recruitment Mailing The SvO, Study, General Design and Formats and Two Messages about a Results of the Feasibility Phase of a Nutrition Program for Women Multicenter, Randomized Trial of 50-79 Years Old, 422 Three Different Hemodynamic Response to Discussants’ Letters, 310 Approaches and Two Monitoring Response to “Inclusion of Women and Techniques in the Treatment of Minorities in Clinical Trials and the Critically Il] Patients, 74 NIH Revitalization Act of 1993 —the Perspective of NIH Clinical DATA AND SAFETY Trialists, 286, 289, 293, 296, 299 MONITORING BOARDS Use of Cumulative Meta-Analysis in the The Data and Safety Monitoring Board and Design, Monitoring, and Final Acquired Immune Deficiency Analysis of a Clinical Trial: A Case Syndrome (AIDS) Clinical Trials, Study, 331 408 CLINIMETRICS DATA COLLECTION Assessing the Quality of Randomized Format-Independent Data Collection Controlled Trials: An Annotated Forms, 363 Bibliography of Scales and Checklists, 62 DATA ENTRY Response to Dr. Blumenstein’s Letter CLUSTER RANDOMIZATION (letter), 455 Statistical Design of the Child and Adolescent Trial for Cardiovascular DATA MANAGEMENT Health (CATCH): Implications of Approaches to Data Management, 30S Cluster Randomization, 96 Data Collection and Transcription, 66S Data Management for Multicenter Studies: COMMUNITY STUDIES Methods and Guidelines, 1S Statistical Design of the Child and Data Quality Assurance, Monitoring, and Adolescent Trial for Cardiovascular Reporting, 104S Health (CATCH): Implications of Interim Reports, Participant Closeout, and Cluster Randomization, 96 Study Archives, 137S Subject Index for Volume 16 DATA QUALITY Epidemiology, 230 An Assessment of Data Quality in the Vermont-Oxford Trials Network EQUIVALENCE STUDIES Database, 51 Conventional Null Hypothesis Testing in Active Control Equivalence DATABASE Studies, 356 An Assessment of Data Quality in the Vermont-Oxford Trials Network ERROR RATES Database, 51 An Assessment of Data Quality in the Vermont-Oxford Trials Network DAVID BYAR Database, 51 David Byar’s Approach to the Analysis of Survival Data with Covariates, 259 FETAL HEMOGLOBIN Design of the Multicenter Study of DEVICE APPROVAL : Hydroxyurea in Sickle Cell Anemia, Observational versus Randomized Medical 432 Device Testing Before and After Approval — The Atherectomy- FIRST ADMINISTRATION versus-Angioplasty Controversy, Dose-Ranging Trials: Guidelines for Data Collection and Standardized 143 Descriptions, 319 DISCRIMINANT REGIONS A Simple Measure in Defining Optimal FISHER’s LSD APPROACH Design and Analysis of Multiarm Clinical Strata in Clinical Trials, 164 Trials with Survival Endpoints, 119 DISEASE PREVENTION TRIALS FOLLOW-UP STUDIES On the Role, Design, and Analysis of Format-Independent Data Collection Disease Prevention Trials, 249 Forms, 363 DOSE RANGING FOOD AND DRUG ADMINISTRATION Dose-Ranging Trials: Guidelines for Data Observational versus Randomized Medical Collection and Standardized Device Testing Before and After Descriptions, 319 Approval— The Atherectomy- versus-Angioplasty Controversy, DRUG THERAPY A Randomized Trial to Assess Effectiveness 143 and Cost in Clinical Practice: FORM PRODUCTION Rationale and Design of the Format-Independent Data Collection Cholesterol Reduction Intervention Forms, 363 Study (CRIS), 3 GROUP RANDOMIZATION ECONOMIC INVESTIGATION Statistical Design of the Child and The Clinical-Economic Trial: Promise, Adolescent Trial for Cardiovascular Problems, and Challenges, 377 Health (CATCH): Implications of Cluster Randomization, 96 EDUCATION An Empirical Evaluation of the Placebo HEAD INJURY Run-in, 41 A Simple Measure in Defining Optimal Strata in Clinical Trials, 164 ELICITATION Prime Time for Bayes, 313 HEMODYNAMICS The SvO, Study: General Design and EPIDEMIOLOGIC METHODS Results of the Feasibility Phase of a The Clinical-Economic Trial: Promise, Multicenter, Randomized Trial of Problems, and Challenges, 377 Three Different Hemodynamic Approaches and Two Monitoring EPIDEMIOLOGY Techniques in the Treatment of David Byar’s Contribution to Critically Ill Patients, 74 Subject Index for Volume 16 465 HOTELLINGS T? Response to S.J. Day’s Letter, 447 Comment on the Substitution of z for t and Sample Size Calculations for Repeated on Hotelling’s T* for Repeated Measures Experiments, 449 Measures (letter), 451 LOGRANK TEST HYDROXYUREA Design and Analysis of Multiarm Clinical Design of the Multicenter Study of Trials with Survival Endpoints, 119 Hydroxyurea in Sickle Cell Anemia, 432 LOSS FUNCTION Prime Time for Bayes, 313 HYPERCHOLESTEROLEMIA A Randomized Trial to Assess Effectiveness MAILINGS and Cost in Clinical Practice: Response Rates to Six Recruitment Mailing Rationale and Design of the Formats and Two Messages about a Cholesterol Reduction Intervention Nutrition Program for Women Study (CRIS), 3 50-79 Years Old, 422 INTENSIVE CARE MANTEL — HAENSZEL STATISTIC The SvO, Study: General Design and A Simple Measure in Defining Optimal Results of the Feasibility Phase of a Strata in Clinical Trials, 164 Multicenter, Randomized Trial of Three Different Hemodynamic MARK-UP LANGUAGE Approaches and Two Monitoring Format-Independent Data Collection Techniques in the Treatment of Forms, 363 Critically Ill Patients, 74 MARKOV MODEL INTENTION-TO-TREAT PRINCIPLE Sample Size Calculation for Complex Statistical Design of the Child and Clinical Trials with Survival Adolescent Trial for Cardiovascular Endpoints, 395 Health (CATCH): Implications of Cluster Randomization, 96 MEASUREMENT Comment on the Substitution of z for t and INTERACTIONS on Hotelling’s T? for Repeated David Byar’s Approach to the Analysis of Measures (letter), 451 Survival Data with Covariates, 259 META-ANALYSIS INTERIM REPORTING Problems and Suggested Solutions in Interim Reports, Participant Closeout, and Creating an Archive of Clinical Study Archives, 137S Trials Data to Permit Later Meta-Analysis: An Example of LAG TIME Methotrexate Trials in Rheumatoid Sample Size Calculation for Complex Arthritis, 342 Clinical Trials with Survival Use of Cumulative Meta-Analysis in the Endpoints, 395 Design, Monitoring, and Final Analysis of a Clinical Trial: A Case LEAST FAVORABLE ALTERNATIVE Study, 331 Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119 MINORITIES Commentary Regarding “Inclusion of LETTERS TO THE EDITOR Women and Minorities in Clinical Comment on the Substitution of z for t and Trials and the NIH Revitalization Act on Hotelling’s T? for Repeated of 1993—The Perspective of NIH Measures, 451 Clinical Trialists,” 307 A Further Look at the Comments on NIH Clinical Trials Valid Cochran-Mantel-Haenszel Risk Analysis Requirements, 304 Difference, 359 Discussion of “Inclusion of Women and Medical Research Data, 453 Minorities in Clinical Trials and the Response to Dr. Blumenstein’s Letter, 455 NIH Revitalization Act of 1993 — The Subject Index for Volume 16 Perspective of NIH Clinical Women and Minorities in Clinical Trialists,” 301 Trials and the NIH Revitalization Act Inclusion of Women and Minorities in of 1993 — The Perspective of NIH Clinical Trials, 290 Clinical Trialists,” 307 Inclusion of Women and Minorities in Comments on NIH Clinical Trials Valid Clinical Trials and the NIH Analysis Requirements, 304 Revitalization Act of 1933—The Discussion of “Inclusion of Women and Perspective of NIH Clinical Minorities in Clinical Trials and the Trialists,” 277 NIH Revitalization Act of 1993 —The Response to Discussants’ Letters, 310 Perspective of NIH Clinical Response to “Inclusion of Women and Trialists,” 301 Minorities in Clinical Trials and the Impact of the NIH Inclusion Guidelines, NIH Revitalization Act of 1993 — The 300 Perspective of NIH Clinical Inclusion of Women and Minorities in Trialists,” 286, 289, 293, 296, 299 Clinical Trials, 290 Inclusion of Women and Minorities in MIXTURE SURVIVAL MODEL Clinical Trials and the NIH Cost Utility Analysis of Maintenance Revitalization Act of 1933—The Treatment for Recurrent Perspective of NIH Clinical Depression, 17 Trialists, 277 Response to Discussants’ Letters, 310 MONITORING TECHNIQUES Response to “Inclusion of Women and Design of the Prostate Cancer Prevention Minorities in Clinical Trials and the Trial (TCPT), 150 NIH Revitalization Act of 1993 —the Perspective of NIH Clinical MONTE CARLO SIMULATION Trialists,” 286, 289, 293, 296, 299 Cost Utility Analysis of Maintenance Treatment for Recurrent NONPROPORTIONAL HAZARDS Depression, 17 Sample Size Calculation for Complex Clinical Trials with Survival MULTICENTER STUDIES Endpoints, 395 Data Management for Multicenter Studies: Methods and Guidelines, 1S NULL HYPOTHESIS Functins and Organization of Coordinating Conventional Null Hypothesis Testing in Centers for Multicenter Studies, 4S Active Control Equivalence Studies, 356 MULTILEVEL MODELING Statistical Design of the Child and OBJECTIVITY Adolescent Trial for Cardiovascular Prime Time for Bayes, 313 Health (CATCH): Implications of Cluster Randomization, 96 OBSERVATIONAL DATA Observational versus Randomized Medical MULTIPLE COMPARISON Device Testing Before and After Design and Analysis of Multiarm Clinical Approval-The Atherectomy-versus- Trials with Survival Endpoints, 119 Angioplasty Controversy, 143 NEONATE OPTICAL CATHETER An Assessment of Data Quality in the The SvO, Study: General Design and Vermont-Oxford Trials Network Results of the Feasibility Phase of a Database, 51 Multicenter, Randomized Trial of Three Different Hemodynamic NETWORK Approaches and Two Monitoring An Assessment of Data Quality in the Techniques in the Treatment of Vermont-Oxford Trials Network Critically Ill Patients, 74 Database, 51 OXYGEN DELIVERY NIH REVITALIZATION ACT The SvO, Study: General Design and Commentary Regarding “Inclusion of Results of the Feasibility Phase of a Subject Index for Volume 16 Multicenter, Randomized Trial of QUALITY Three Different Hemodynamic Assessing the Quality of Randomized Approaches and Two Monitoring Controlled Trials: An Annotated Techniques in the Treatment of Bibliography of Scales and Critically Il] Patients, 74 Checklists, 62 PARTICIPANT CLOSEOUT QUALITY ASSURANCE Interim Reports, Participant Closeout, and Data Quality Assurance, Monitoring, and Study Archives, 137S Reporting, 104S PHASE I STUDY RANDOMIZED CLINICAL TRIAL Dose-Ranging Trials: Guidelines for Data A Randomized Trial to Assess Effectiveness Collection and Standardized and Cost in Clinical Practice: Descriptions, 319 Rationale and Design of the Cholesterol Reduction Intervention PLACEBO Study (CRIS), 3 An Empirical Evaluation of the Placebo Run-in, 41 RANDOMIZED CONTROLLED TRIALS The Clinical-Economic Trial: Promise, POSTERIOR DISTRIBUTION Problems, and Challenges, 377 Prime Time for Bayes, 313 Observational versus Randomized Medical Device Testing Before and After POWER Approval — The Atherectomy- Design and Analysis of Multiarm Clinical versus-Angioplasty Controversy, Trials with Survival Endpoints, 119 143 PREOPERATIVE RISK ASSESSMENT RECRUITMENT Requirements for Controlled Clinical Trials Response Rates to Six Recruitment Mailing of Preoperative Cardiovascular Formats and Two Messages about a Risk Reduction, 89 Nutrition Program for Women 50-79 Years Old, 422 PREOPERATIVE CARDIAC TESTING Requirements for Controlled Clinical Trials RECURRENT DEPRESSION of Preoperative Cardiovascular Cost Utility Analysis of Maintenance Risk Reduction, 89 Treatment for Recurrent Depression, 17 PREVENTION TRIALS Response Rates to Six Recruitment Mailing REGISTER OF TRIALS Formats and Two Messages about a UKCCCR Register of U.K. Cancer Trials, Nutrition Program for Women 50-79 Years old, 422 172 REPEATED MEASURES EXPERIMENTS PRIOR DISTRIBUTION Sample Size Calculations for Repeated Prime Time for Bayes, 313 Measures Experiments (letter), 449 PROSTATE CANCER Design of the Prostate Cancer Prevention RESPONSE RATES Trial (TCPT), 150 Response Rates to Six Recruitment Mailing Formats and Two Messages about a PROTOCOL Nutrition Program for Women 50-79 Years Old, 422 Dose-Ranging Trials: Guidelines for Data Collection and Standardization Descriptions, 319 RISK DIFFERENCE ESTIMATORS A Further Look at the PULMONARY FUNCTION TESTS Cochran-Mantel-Haenszel Risk Response to S.J. Day Letter (letter), 447 Difference (letter), 359 Subject Index for Volume 16 RUN-IN THERAPEUTIC TRIALS An Empirical Evaluation of the Placebo On the Role, Design, and Analysis of Run-in, 41 Disease Prevention Trials, 249 SAMPLE SIZE TIME-DEPENDENT RATES Comment in the Substitution of z for t and Sample Size Calculation for Complex on Hotelling’s T? for Repeated Clinical Trials with Survival Measures (letter), 451 Endpoints, 295 Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119 TRIAL REGISTRY Sample Size Calculations for Repeated UKCCCR Register of U.K. Cancer Trials, Measures Experiments (letter), 449 172 SCALES TYPE I ERROR Assessing the Quality of Randomized Design and Analysis of Multiarm Clinical Controlled Trials: An Annotated Trials with Survival Endpoints, 119 Bibliography of Scales and Checklists, 62 UNCONDITIONAL POWER Sample Size Calculation for Complex SICKLE CELL ANEMIA Clinical Trials with Survival Design of the Multicenter Study of Endpoints, 295 Hydroxyurea in Sickle Cell Anemia, 432 UTILITY FUNCTION Prime Time for Bayes, 313 SICKLE CELL CRISES PREVENTION Design of the Multicenter Study of VALID ANALYSIS Hydroxyurea in Sickle Cell Anemia, Comments on NIH Clinical Trials Valid 432 Analysis Requirements, 304 SOCIETY FOR CLINICAL TRIALS WOMEN Sixteenth Annual Meeting, 3S Commentary Regarding “Inclusion of Women and Minorities in Clinical STANDARDS Trials and the NIH Revitalization Act Dose-Ranging Trials: Guidelines for Data of 199— 3Th e Perspective of NIH Collection and Standardized Clinical Trialists,” 307 Descriptions, 319 Comments on NIH Clinical Trials Valid Analysis Requirements, 304 STRATIFICATION Discussion of “Inclusion of Women and A Simple Measure in Defining Optimal Strata in Clinical Trials, 164 Minorities in Clinical Trials and the NIH Revitalization Act of 1993 — The STUDY ARCHIVING Perspective of NIH Clinical Interim Reports, Participant Closeout, and Trialists,” 301 Study Archives, 137S Inclusion of Women and Minorities in Clinical Trials, 290 SUBJECTIVITY Inclusion of Women and Minorities in Prime Time for Bayes, 313 Clinical Trials and the NIH Revitalization Act of 1993—The SURVIVAL ANALYSIS WITH Perspective of NIH Clinical COVARIATES Trialists, 277 David Byar’s Approach to the Analysis of Response to Discussants’ Letters, 310 Survival Data with Covariates, 259 Response to “Inclusion of Women and Minorities in Clinical Trials and the SURVIVAL ENDPOINTS NIH Revitalization Act of 1993 — The Design and Analysis of Multiarm Clinical Perspective of NIH Clinical Trials with Survival Endpoints, 119 Trialists,” 286, 289, 293, 296, 299